Teijin Limited

Theravalues Corporation

Other

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Kyoto University

Therabiopharma Inc.

Atsushi Imaizumi

Masahiro Okada

Yorimasa Suwa

Keizo Inoue

Yoji Suzuki

Ichiro Kudo

Takashi Kamimura

Yutaka Kawakami

Tomonori Yaguchi

Hitomi Ozawa

Taeko Hayakawa

Takashi Sugiyama

Kazuya Takenouchi

Hirofumi Takeuchi

Yoshihiko Sumi

Iwao Yoshida

Kenichi Masuda

Seiichi Ishizuka

Yuji Sato

Hisao Yamaguchi

Hiroshi Imai

Daishiro Miura

Eiko Ohtsuka

Shoji Ono

Noriyoshi Kurihara

Kiyoyuki Sakon

Masashi Kanai

Kohei Tahara

Hideaki Kakeya

Yohichi Matsumoto

Tetsuya Suga

Yasuhiro Oue

Tsukasa Takahashi

Yoshimitsu Naniwa

Akiko Takeuchi

Kunihito Watanabe

Zhi Zhang

Declan P Naughton

Hiroko Sato

Chieko Azuma

Masaharu Kanesaki

Tadashi Hashimoto

Nobuaki Takahashi

Takato Matsui

Sakamuri V Reddy

G David Roodman

Mitsuru Kobayashi

Provided is a curcumin pharmaceutical preparation that is highly water soluble, can maintain the concentration of free curcumin in the blood sufficiently high by being administered parenterally, can effectively obtain a pharmacological action of curcumin, and is highly safe. A pharmaceutical composition for parenteral administration, including a water-soluble substance conjugate of curcumin as an active component.

Drug composition for parenteral administration

To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.

Therapeutic agent for cancer

Formulation of curcumin and anti-PD-1 antibody

Provided is a composition for oral intake, which exhibits improved oral absorbability of curcumin and/or an analog thereof and can be produced conveniently and inexpensively. A complex of curcumin and/or an analog thereof and a water-soluble cellulose derivative is disclosed.

Composition for oral intake

To obtain a treating agent for Paget's disease of bone, there is provided a method of inhibiting expression of general transcription factor of steroid hormone receptor.

Treating agent for Paget's disease of bone

Glutathione derivatives and their dosage forms

Compounds for use in the treatment of heart disease include a superoxide scavenger and an organic nitrate or nitrite moiety. The compounds can be represented by the formula (A)n(B)m, in which A is a superoxide scavenger, B is an organic nitrate or organic nitrite moiety, and n and m are values between 1 and 8. These compounds do not suffer from the problem of patient tolerance that is associated with the use of conventional agents such as organic nitrates.

Chemical compound containing a superoxide scavenger and an organic nitrate or nitrite moiety

The present invention provides an elastase inhibitory polypeptide comprising a C-terminal half of a human secretory leukocyte protease inhibitor (SLPI) and having an elastase inhibitory activity wherein inhibitory activity of a trypsin-like serine protease does not exceed 1/10 of elastase inhibitory activity, and polypeptides having the above-mentioned biological activity wherein one or more than one amino acid is added, one or more than one amino acid is deleted and/or one or more than one amino acid is replaced. The present invention also provides a process for the production of the above-mentioned protein or other protein via a corresponding fused protein.

Elastase inhibitory polypeptide and process for production thereof by

Peptide inhibitors of phospholipase A.sub.2 purified from inflammatory

Protein inhibitors of phospholipase A.sub.2 purified from inflammatory sites which have an amino acid sequence given in FIGS. 3-1 through 3-3 or an amino acid sequence physiologically equivalent thereto, a process for preparation of said inhibitory protein wherein serum of mammalian animal is enzymatically treated, and a gene coding said inhibitory protein.

Protein inhibitors of phospholipase A.sub.2 purified from inflammatory

A Bordetella pertussis variant which produces a pertussis toxin mutant protein partially devoid of subunits. When the variants of the present invention are cultured, a pertussis toxin mutant protein partially devoid of subunits, particularly at least subunit S1, can be harvested from the culture. The thus-obtained pertussis toxin mutant protein partially devoid of subunits can be applied to the preparation of a pertussis vaccine by a conventional method.

Bordetella pertussis variants

Protein having an inflammatory phospholipase A.sub.2 inhibitory activity

Protein having a phospholipase A.sub.2 inhibitory activity which has the nature to be induced from cells upon administration of glucocorticoid and has a phospholipase A.sub.2 inhibitory activity.

Protein having phospholipase A2 inhibitory activity

A method of culturing microbes which belong to the genus Bordetella characterized by adding cyclodextrin or its derivative to the culture medium used for cultivating microbes belonging to the genus Bordetella and a culture medium therefor.

Culturing Bordetella in media containing etherified cyclodextrin

Growing community of inventors

Hino, Japan

Atsushi Imaizumi